Of the most frequently mutated genes in HNSCC, only those with oncogenic mutations in PIK3CA and HRAS can be targeted with small molecule inhibitors that are currently in preclinical testing for HNSCC and other malignancies (see Section 4). Here, HRAS is linked to head and neck squamous cell carcinoma.